Notice of Effectiveness · EFFECT
Talawar Tx Inc.
Notice of Effectiveness
Structured filing — EFFECT
primary_doc.xml
Notice details
- Submission type
- EFFECT
- Act
- 33
Effectiveness
- Effective date
- 2026-11-09
- Effective time (as filed)
- 16:00:00
- Form
- S-4
Registrant 1
- Registrant
- Talawar Tx Inc.
- Registrant CIK
- 0002140859
- File number
- 333-298621
Company context
Talawar Therapeutics is a biotechnology company developing potentially best-in-class bispecific antibodies that pair independent disease drivers in a single therapy, targeting pathways that work together for greater, more durable impact. Our lead program, TALA-125, is a novel anti-IL-13 x anti-IL-18 bispecific that combines two clinically validated, largely orthogonal mechanisms designed to shatter the current limitations of existing treatments - with broad applicability across first-line patients and those who have failed previous therapies. Talawar is the first company formed to develop and commercialize assets discovered by Khanda Therapeutics, L.P. For more information, visit www.talawartx.com.